Skip to main content
Therma Bright Inc. logo

Therma Bright Inc. — Investor Relations & Filings

Ticker · THRM ISIN · CA8834262070 LEI · 529900PN7P0GSORO2174 TSXV Manufacturing
Open in API
Filings indexed 525 across all filing types
Latest filing 2022-02-19 Capital/Financing Update
Country CA Canada
Listing TSXV THRM

About Therma Bright Inc.

https://www.thermabright.com/

Therma Bright Inc. is a medical technology company that develops, acquires, and markets proprietary diagnostic and medical device technologies for the consumer and institutional healthcare sectors. The company's portfolio addresses key areas including pain management, circulation, diagnostics, and critical care. Core products and development projects include Venowave, a medical device designed to boost circulation and prevent blood clots; the Digital Cough Test (DCT), an AI-powered application developed with AI4LYF for rapid, non-invasive detection of respiratory diseases; and the PREVA™ clot retriever, developed with Inretio for enhanced thrombectomy procedures in ischemic stroke treatment. Furthermore, Therma Bright is advancing inhaled statin therapy in partnership with InVixa for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS).

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a private placement financing by Therma Bright Inc. It details the amount raised (CAD$6 million), the issuance of common shares and warrants, the use of proceeds, and the involvement of a placement agent. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on capital raising activities and financing terms. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2022-02-19 English
Material change report - English.pdf
Regulatory Filings
2022-02-19 English
Material change report - English.PDF
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report, which is a regulatory filing used to disclose significant corporate events. The content describes a private placement financing transaction, including details about the issuance of common shares and warrants, the amount raised (CAD$6 million), and the use of proceeds. It is not a full financial report but an announcement of a capital raising event. The document is about a financing update rather than an annual or quarterly report, audit, or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-02-18 English
News release - English.PDF
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a CAD$6 million private placement of common shares and warrants by Therma Bright Inc. It details the terms of the private placement, the use of proceeds, and regulatory disclaimers related to securities laws. There is no financial data, earnings information, or detailed report content. The focus is on a financing activity involving issuance of shares and warrants to institutional investors. This fits the category of Capital/Financing Update (CAP). The document length is about 5118 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Therefore, the classification is CAP with high confidence.
2022-02-18 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the successful completion of a clinical performance study for Therma Bright's AcuVid COVID-19 Rapid Antigen Saliva Test, exceeding FDA Emergency Use Authorization requirements. It discusses study results, ongoing FDA submission plans, and marketing contracts. There are no financial statements, regulatory filings, or detailed financial data. The content is primarily an announcement of clinical study results and company updates, not a formal financial or regulatory report. It does not fit categories like Annual Report, Interim Report, or Regulatory Filings. It is a general company announcement about product development and clinical study success, which aligns best with Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2022-02-15 English
News release - English.pdf
Regulatory Filings
2022-01-31 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.